BIOA

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target the biology of human aging to treat age-related diseases. Headquartered in Richmond, California, BioAge has pioneered a data-driven approach combining human longevity data, machine learning, and experimental biology to identify therapeutic targets associated with healthy aging. The company's mission centers on extending human healthspan by developing drugs that modify aging processes to prevent or treat multiple age-related diseases simultaneously. BioAge's lead program is azelaprag, a selective small molecule agonist of the apelin receptor being developed for obesity, metabolic disease, and potentially other age-related conditions. The apelin pathway plays roles in metabolism, muscle function, and other processes that decline with aging. Clinical trials have evaluated azelaprag in obesity and shown encouraging results on weight loss and metabolic parameters. BioAge's pipeline includes additional programs targeting biological mechanisms of aging including muscle maintenance, metabolic health, and inflammation. The company's discovery platform leverages large-scale human genetic and clinical datasets combined with machine learning to identify genetic signatures associated with longer, healthier lifespans. This approach aims to identify therapeutic targets and patient populations most likely to benefit from interventions. BioAge addresses a fundamental shift in medicine toward targeting aging biology rather than individual diseases. The aging biology field is attracting significant scientific and investment interest as understanding grows about common mechanisms underlying multiple age-related conditions. BioAge's success depends on demonstrating clinical efficacy and safety, completing regulatory pathways, and proving that targeting aging mechanisms delivers meaningful patient outcomes. The company competes in an emerging field against both specialized aging-biology companies and traditional pharmaceutical firms increasingly interested in longevity science.